Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage. Economic evaluation of a phase III clinical trial in Europe and Australia.


Journal Article

This study used data from a multinational phase III randomized, double-blind, vehicle-controlled trial to evaluate the cost-effectiveness of tirilazad mesylate (Freedox) in the treatment of aneurysmal subarachnoid hemorrhage. In men, therapy with 6 mg/kg per day of tirilazad mesylate was associated with significantly increased survival, increased cost of care, and ratios of cost per death averted that compare favorably with the ratios of other life and death interventions. In women, it appeared to have no effects on costs or survival. Further clinical studies may provide additional information about the cost-effectiveness of this intervention.

Full Text

Cited Authors

  • Glick, H; Willke, R; Polsky, D; Llana, T; Alves, WM; Kassell, N; Schulman, K

Published Date

  • January 1998

Published In

Volume / Issue

  • 14 / 1

Start / End Page

  • 145 - 160

PubMed ID

  • 9509802

Pubmed Central ID

  • 9509802

Electronic International Standard Serial Number (EISSN)

  • 1471-6348

International Standard Serial Number (ISSN)

  • 0266-4623

Digital Object Identifier (DOI)

  • 10.1017/s026646230001059x


  • eng